A phase 2 proof-of-concept study of gevokizumab in subjects with inflammatory erosive osteoarthritis of the hand
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2014
Price : $35 *
At a glance
- Drugs Gevokizumab (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors XOMA
- 03 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jul 2013 40 patients have been recruited so far, according to a media release from XOMA.
- 26 Jun 2013 New trial record